Disease Landscape and Forecast Insights

Clarivate Epidemiology’s coverage of hepatitis B virus (HBV) infection comprises epidemiological estimates of key patient populations in 45 countries. We report the total prevalence of HBV…

Clarivate Epidemiology’s coverage of hepatitis B virus (HBV) infection comprises epidemiological estimates of key patient populations in 45 countries. We report the total prevalence of HBV…

Clarivate Epidemiology’s coverage of hepatitis B virus (HBV) infection comprises epidemiological estimates of key patient populations in 45 countries. We report the total prevalence of HBV…

Clarivate Epidemiology’s coverage of hepatitis B virus (HBV) infection comprises epidemiological estimates of key patient populations in 45 countries. We report the total prevalence of HBV in…

Clarivate Epidemiology’s coverage of hepatitis B virus (HBV) infection comprises epidemiological estimates of key patient populations in 45 countries. We report the total prevalence of HBV…

CAR T-cell therapies have given new hope to patients with relapsed/refractory (R/R) non-Hodgkin’s lymphoma (NHL) and more recently to patients with R/R multiple myeloma. Priced at more than $350,…

Since the approval of the first biosimilar in Europe more than a decade ago, the adoption of biosimilars has been increasing among all specialties. The FDA approved Sandoz’s Zarxio (filgrastim)…

Clarivate Epidemiology’s coverage of SLE comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed prevalence and the diagnosed…

The treatment landscape for COVID-19 continues to evolve rapidly. Even with vaccines having become available in the markets under study, intense ongoing research has also focused on approaches…

Biosimilars of erythropoiesis-stimulating agents (ESAs) entered the European market a decade ago, but the FDA did not approve the first ESA biosimilar—Retacrit—until June 2018; it launched in…

Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity…

In 2019, Amgen / Allergan’s trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by…